A5021522275- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Neuroendocrine Tumor Research Advances
- Bariatric Surgery and Outcomes
- Diabetes Management and Research
- Pancreatic function and diabetes
- Cardiovascular Function and Risk Factors
- Growth Hormone and Insulin-like Growth Factors
- Alcohol Consumption and Health Effects
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Fibroblast Growth Factor Research
- Kruppel-like factors research
- Neuropeptides and Animal Physiology
- Regulation of Appetite and Obesity
- Bone health and osteoporosis research
- Diet and metabolism studies
- Bone Metabolism and Diseases
- Bone health and treatments
- Cardiac and Coronary Surgery Techniques
- Liver Disease Diagnosis and Treatment
University of Copenhagen
2019-2024
Gentofte Hospital
2018-2024
Steno Diabetes Centers
2019
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted postprandially contribute importantly to postprandial glucose tolerance. In this study, we assessed the individual combined contributions of endogenous GIP GLP-1 changes in glucoregulatory using novel receptor antagonist GIP(3-30)NH2 well-established exendin(9-39)NH2 During 4-h oral tolerance tests (75 g) with an ad libitum meal test, 18 healthy men received on four...
Abstract Context The actions of both endogenous incretin hormones during a meal have not previously been characterized. Objective Using specific receptor antagonists, we investigated the individual and combined contributions glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide 1 (GLP-1) to postprandial glucose metabolism, energy expenditure, gallbladder motility. Design Randomized, double-blinded, placebo-controlled, crossover design. Setting On four separate days, liquid...
Postbariatric hypoglycemia affects >50% of individuals who have undergone Roux-en-Y gastric bypass surgery. Despite the often debilitating nature this complication, existing treatment options are limited and inefficient. Dasiglucagon is a stable glucagon analog available in ready-to-use formulation was recently shown to mitigate postbariatric experimental settings. Here, we aimed evaluate hypoglycemic hindering potential dasiglucagon an outpatient trial.We conducted randomized, double-blind,...
Ingestion of the calorically dense compound alcohol may cause metabolic disturbances including hypoglycaemia, hepatic steatosis and insulin resistance, but underlying mechanisms are uncertain. The gastrointestinal tract is well recognised as a major influencer on glucose, protein lipid metabolism, its role in metabolism remains unclear.To examine effects oral intravenous alcohol, respectively, plasma concentrations several gluco-regulatory hormones serum/plasma insulin, C-peptide, glucagon,...
The incretin hormone glucose-dependent insulinotropic polypeptide (GIP) is secreted from enteroendocrine K cells in the small intestine following food intake. Exogenous GIP stimulates glucagon secretion during fasting at low blood sugar and exerts anabolic effects fat bone healthy individuals. Using receptor antagonist GIP(3-30)NH2, we investigated of endogenous humans fasting. In a randomized, placebo-controlled, double-blind, crossover study comprising two experimental days, 12...
The gut-derived incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are known for glucose-lowering effects. However, their individual roles in postprandial glucose homeostasis unknown. We infused the GIP receptor antagonist GIP(3-30)NH2 GLP-1 exendin(9-39) during a meal to determine of endogenous on metabolism. On four separate days, 12 healthy men (age 19-65 years, BMI 20-25 kg/m2) received liquid mixed test with randomized double-blinded...
The insulinotropic effect of exogenous glucose-dependent polypeptide (GIP) is severely reduced or even absent in persons with type 2 diabetes but may be partly regained following improved glycemic control. Here, we examined the beta cell response to endogenous GIP before and after a period plasma glucose (PG) normalization. In randomized, double-blind design, 15 metformin-treated dysregulated (HbA1c 8.3±0.3% (67±3 mmol/mol) ([mean±SEM]) were subjected two 75 g-oral tolerance tests (OGTT)...
Due to reports of severely reduced insulinotropic effect the incretin hormone glucose-dependent polypeptide (GIP) in type 2 diabetes (T2D), GIP has not been considered therapeutically viable. Recently, however, tirzepatide, a novel dual receptor agonist (activating and glucagon-like peptide 1 (GLP-1) receptor) demonstrated greater glucose body weight-lowering properties as compared GLP-1 therapy. The contribution activation effects tirzepatide remains unknown. We will evaluate...
<p dir="ltr">Objective: Post-bariatric hypoglycemia affects more than 50% of Roux-en-Y gastric bypass-operated individuals. Despite the often debilitating nature this complication, existing treatment options are limited and inefficient. Dasiglucagon is a stable glucagon analog available in ready-to-use formulation recently shown to mitigate post-bariatric experimental settings. Here we aimed evaluate hypoglycemic hindering potential dasiglucagon an outpatient trial.</p><p...
<p dir="ltr">Objective: Post-bariatric hypoglycemia affects more than 50% of Roux-en-Y gastric bypass-operated individuals. Despite the often debilitating nature this complication, existing treatment options are limited and inefficient. Dasiglucagon is a stable glucagon analog available in ready-to-use formulation recently shown to mitigate post-bariatric experimental settings. Here we aimed evaluate hypoglycemic hindering potential dasiglucagon an outpatient trial.</p><p...
The gut hormone glucose-dependent insulinotropic polypeptide (GIP) stimulates glucose-induced insulin secretion and increases triglyceride deposition in subcutaneous adipose tissue, these effects are attenuated both type 2 diabetes (T2D) obesity. Using the GIP receptor antagonist (3-30) NH2, we investigated effect of endogenous on circulating lipoproteins (chylomicrons, VLDL, LDL, HDL) during a meal healthy men patients with T2D. We measured apolipoprotein B48 (ApoB48) (as marker chylomicron...